Fig. 2 | Blood Cancer Journal

Fig. 2

From: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Fig. 2

Best responses to GSK2857916. a Maximum percentage change from baseline in M-protein or free light chain. For patients with measurable serum M-protein, serum concentration is shown; for patients with urine M-protein measurements, urine concentrations are shown; and for patients with no available serum or urine M-protein measurements, free light-chain concentrations are shown. b Forest plot of overall response rates by patient subgroup. *Defined as prior cyclophosphamide (CTX) regimen with daratumumab as the only drug in the regimen; †defined as prior CTX regimen with daratumumab and other drugs in the regimen; ‡defined as refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab; §a patient is considered as high risk if the subject has any of the following cytogenetics: t(4;14), del17p and t(14;16)

Back to article page